Oct 24, 2024 · expected timing of regulatory filings and the initiation and completion of clinical trials, including the planned BLA submission for NTLA-2002 in 2026; and its expectations for …
CRISPR-Based Therapy for Hereditary Angioedema | NEJM
Oct 24, 2024 · NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 …
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary …
Jan 31, 2024 · NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 …
Intellia doses first subject in trial of NTLA-2002 for HAE
3 days ago · Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat …
Intellia Therapeutics Announces First Patient Dosed in the HAELO …
3 days ago · NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening d. CAMBRIDGE, …
NTLA-2002: CRISPR/Cas9-mediated gene knockout of KLKB1 to …
The emergence of genome editing technologies as a new therapeutic modality offers the promise of curing many genetic diseases. To this end, Intellia Therapeutics is developing NTLA-2002, …
Across all patients, NTLA-2002 led to a 95% mean reduction in monthly HAE attack rate through the latest follow-up assessment; 89% mean reduction in the 16-week primary observation period
Jun 3, 2024 · the primary observation period of the phase 2 portion of the Phase 1/2 study of NTLA-2002 in 2024, and the planned BLA submission for NTLA-2002 in 2026; and its …
RESULTS FROM A PHASE 2, RANDOMIZED, PLACEBO …
NTLA-2002, an investigational one-time in vivo CRISPR-based therapy targeting KLKB1, was well-tolerated and showed clinical efficacy in Ph1 dose escalation of a Ph1/2 study …
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary
Feb 1, 2024 · NTLA-2002 is an in vivo gene-editing therapy based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9. NTLA-2002 …